BioDelivery Sciences International Inc (BDSI:NASDAQ) Investor Relations Material

Overview

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company in the United States which specializes in drug delivery technologies that include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company focuses on delivering innovative and effective solutions for patients with chronic and acute pain conditions. They have developed a range of patented products that are designed to provide unique formulations, enabling better treatment options for patients who are in need of pain relief. The company's mission is to improve the quality of life for patients and make healthcare more accessible and affordable. They are committed to working towards creating value for shareholders and stakeholders, while also maintaining high ethical standards in their operations.

Frequently Asked Questions

What is BioDelivery Sciences International Inc's ticker?

BioDelivery Sciences International Inc's ticker is BDSI

What exchange is BioDelivery Sciences International Inc traded on?

The company's shares trade on the NASDAQ stock exchange

Where are BioDelivery Sciences International Inc's headquarters?

They are based in Raleigh, North Carolina

How many employees does BioDelivery Sciences International Inc have?

There are 201-500 employees working at BioDelivery Sciences International Inc

What is BioDelivery Sciences International Inc's website?

It is http://www.bdsi.com/

What type of sector is BioDelivery Sciences International Inc?

BioDelivery Sciences International Inc is in the Healthcare sector

What type of industry is BioDelivery Sciences International Inc?

BioDelivery Sciences International Inc is in the Biotechnology industry

Who are BioDelivery Sciences International Inc's peers and competitors?

The following five companies are BioDelivery Sciences International Inc's industry peers:

- TG Therapeutics

- Adaptive Biotechnologies

- Solid Biosciences

- Innate Pharma S.A.

- LogicBio Therapeutics, Inc.